Arsenic Trioxide for Structural p53 Mutations

Clinical trial NCT04695223 · UNKNOWN

Trial details

NCT number: NCT04695223
Sponsor: Shanghai Changzheng Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Arsenic Trioxide p53 Mutations Refractory Cancer Intractable Cancer

Start date: 2021-01-01
Primary completion: 2021-08-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.